Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 4/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11682271 | 1.00 | TDP1 (0.60) | TDP1L3MBTL1ACHECHRM2MEN1 | |
| SCHEMBL30601919 | 1.00 | TDP1 (0.60) | TDP1L3MBTL1ACHECHRM2MEN1 | |
| SCHEMBL5818475 | 1.00 | TDP1 (0.60) | TDP1L3MBTL1ACHECHRM2MEN1 | |
| SCHEMBL1162143 | 0.98 | TDP1 (0.57) | TDP1L3MBTL1ACHE | |
| SCHEMBL29773409 | 0.93 | TDP1 (0.54) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL559750 | 0.93 | TDP1 (0.54) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL8862878 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1ACHECHRM2MEN1 | |
| SCHEMBL2604742 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1ACHECHRM2MEN1 | |
| SCHEMBL8863154 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1ACHECHRM2MEN1 | |
| SCHEMBL8862728 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1ACHECHRM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755684-B1 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-7910618-B2 | Polyethylene glycol end-modified by an antibody or maleimide group on one end and a hydroxy fatty acid on the other; increased in vivo half life of insulin; antidiabetic agents | UCB PHARMA S.A. (BE) | 2011-03-22 | — | — | US | disclosed |
| US-7910618-B2 | Polyethylene glycol end-modified by an antibody or maleimide group on one end and a hydroxy fatty acid on the other; increased in vivo half life of insulin; antidiabetic agents | UCB PHARMA S.A. (BE) | 2011-03-22 | — | — | US | disclosed |
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20080096957-A1 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg | CELLTECH R&D LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20080096957-A1 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg | CELLTECH R&D LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| EP-1755684-A2 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | Celltech R&D Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005117984-A2 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | CELLTECH R & D LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
| EP-1585754-A2 | ALKYL-LINKED NUCLEOTIDE COMPOSITIONS | Serenex, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040215009-A1 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2004-10-28 | — | — | US | disclosed |
| WO-2004065566-A2 | ALKYL-LINKED NUCLEOTIDE COMPOSITIONS | SERENEX, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215009-A1 | Alkyl-linked nucleotide compositions | NT5C3B, NUDT1, NT5C2 | TDP1 347/4885L3MBTL1 2948/4885ACHE 4806/4885 |
| US-20080096957-A1 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg | FABP1, FABP2, FABP4 | TDP1 4869/4885L3MBTL1 3928/4885ACHE 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.